Compare CMCSA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCSA | SNY |
|---|---|---|
| Founded | 1963 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.9B | 119.4B |
| IPO Year | 1972 | N/A |
| Metric | CMCSA | SNY |
|---|---|---|
| Price | $27.31 | $48.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 5 |
| Target Price | $37.79 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 32.2M | 2.6M |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | ★ 4.85% | 3.28% |
| EPS Growth | 62.52 | ★ 105.93 |
| EPS | 6.02 | ★ 8.67 |
| Revenue | ★ $123,311,000,000.00 | $53,890,648,839.00 |
| Revenue This Year | $3.00 | $2.48 |
| Revenue Next Year | $2.24 | $6.47 |
| P/E Ratio | ★ $4.53 | $5.61 |
| Revenue Growth | ★ 0.20 | N/A |
| 52 Week Low | $25.75 | $44.62 |
| 52 Week High | $40.37 | $60.12 |
| Indicator | CMCSA | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 43.35 |
| Support Level | $26.45 | $47.80 |
| Resistance Level | $28.08 | $49.24 |
| Average True Range (ATR) | 0.64 | 0.64 |
| MACD | 0.16 | -0.16 |
| Stochastic Oscillator | 47.32 | 29.77 |
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 65 million US homes and businesses, or nearly half of the country. The firm provides services to about half of the locations in this territory. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. The firm plans to spin off most of its cable networks. Finally, Sky, acquired in 2018, is a large television provider in the UK and Italy.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.